Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial

Stephen B. Hanauer*, William J. Sandborn, Asher Kornbluth, Seymour Katz, Michael Safdi, Scott Woogen, Gino Regalli, Chyon Yeh, Nancy Smith-Hall, Funmilay Ajayi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

254 Scopus citations

Fingerprint

Dive into the research topics of 'Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences